Experimental 'Off-the-Shelf' NK cells aim to fight childhood leukemia
NCT ID NCT07406178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests JY509, a universal natural killer (NK) cell therapy, in 18 children with relapsed or refractory B-cell acute lymphoblastic leukemia. The cells are given as a single injection to see if they are safe and can help control the disease. The study uses a dose-escalation design to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JY509 universal NK cell injection
- What this could lead to
- If successful, this could offer a new treatment option for children with hard-to-treat B-cell acute lymphoblastic leukemia.
- What could go wrong
- This is a very early, small trial (18 participants) focused on safety. It may not show strong efficacy, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PEDIATRIC B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.